Sekvensbehandling af postmenopausal osteoporose

Pia Eiken; Jane Dahl Andersen; Anne Pernille Hermann; Jens Erik Beck Jensen; Bente Lomholt Langdahl

doi:10.61409/V03250171

Sekvensbehandling af postmenopausal osteoporose

Translated title of the contribution: Sequence treatment of postmenopausal osteoporosis

Pia Eiken^*
, Jane Dahl Andersen
, Anne Pernille Hermann
, Jens Erik Beck Jensen
, Bente Lomholt Langdahl

^*Corresponding author for this work

Copenhagen University Hospital
Hvidovre Hospital
Aarhus University Hospital

Research output: Contribution to journal › Journal article › Research › peer-review

7 Downloads (Pure)

Abstract

Initial therapy for low-risk patients typically involves potent antiresorptive agents such as bisphosphonates or denosumab to reduce bone resorption and fracture risk. For high-risk patients, bone anabolic agents like teriparatide or romosozumab may be preferred to stimulate bone formation, rapidly increase bone mass and enhance fracture prevention. Effective transitions between therapies are essential to sustain skeletal benefits. This review explores evidence-based strategies for sequential osteoporosis treatment.

Translated title of the contribution	Sequence treatment of postmenopausal osteoporosis
Original language	Danish
Article number	V03250171
Journal	Ugeskrift for Læger
Volume	187
Issue number	23
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V03250171
Publication status	Published - 24. Nov 2025

Documents & Links

10.61409/V03250171Licence: CC BY-NC-ND

Open Access VersionFinal published version, 743 KBLicence: CC BY-NC-ND

SDU Link

Check access to the material in SDU Library's search engine

Cite this

@article{f0ca58adb6624239a90f0f669930d64b,

title = "Sekvensbehandling af postmenopausal osteoporose",

abstract = "Initial therapy for low-risk patients typically involves potent antiresorptive agents such as bisphosphonates or denosumab to reduce bone resorption and fracture risk. For high-risk patients, bone anabolic agents like teriparatide or romosozumab may be preferred to stimulate bone formation, rapidly increase bone mass and enhance fracture prevention. Effective transitions between therapies are essential to sustain skeletal benefits. This review explores evidence-based strategies for sequential osteoporosis treatment.",

author = "Pia Eiken and Andersen, \{Jane Dahl\} and Hermann, \{Anne Pernille\} and \{Beck Jensen\}, \{Jens Erik\} and Langdahl, \{Bente Lomholt\}",

year = "2025",

month = nov,

day = "24",

doi = "10.61409/V03250171",

language = "Dansk",

volume = "187",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "L{\ae}geforeningen",

number = "23",

}

TY - JOUR

T1 - Sekvensbehandling af postmenopausal osteoporose

AU - Eiken, Pia

AU - Andersen, Jane Dahl

AU - Hermann, Anne Pernille

AU - Beck Jensen, Jens Erik

AU - Langdahl, Bente Lomholt

PY - 2025/11/24

Y1 - 2025/11/24

N2 - Initial therapy for low-risk patients typically involves potent antiresorptive agents such as bisphosphonates or denosumab to reduce bone resorption and fracture risk. For high-risk patients, bone anabolic agents like teriparatide or romosozumab may be preferred to stimulate bone formation, rapidly increase bone mass and enhance fracture prevention. Effective transitions between therapies are essential to sustain skeletal benefits. This review explores evidence-based strategies for sequential osteoporosis treatment.

AB - Initial therapy for low-risk patients typically involves potent antiresorptive agents such as bisphosphonates or denosumab to reduce bone resorption and fracture risk. For high-risk patients, bone anabolic agents like teriparatide or romosozumab may be preferred to stimulate bone formation, rapidly increase bone mass and enhance fracture prevention. Effective transitions between therapies are essential to sustain skeletal benefits. This review explores evidence-based strategies for sequential osteoporosis treatment.

U2 - 10.61409/V03250171

DO - 10.61409/V03250171

M3 - Tidsskriftartikel

C2 - 41251243

SN - 0041-5782

VL - 187

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 23

M1 - V03250171

ER -

Sekvensbehandling af postmenopausal osteoporose

Abstract

Documents & Links

SDU Link

Fingerprint

Cite this